The impact of antiviral therapy for hepatitis C on the quality of life: a perspective

Abstract

Instruments to assess the impact of hepatitis C virus infection on health and measurements of reported outcomes in patients (health- related quality of life [HRQOL]) are not frequently used to assign priority for treatment. Several systematic reviews have been performed that provide a comprehensive analysis to help understand patient reported outcomes (PROs) with direct acting antiviral treatment. Clinical trials with direct acting antivirals (DAAs) provide an important opportunity to assess PROs without interferon or ribavirin. Significant improvement in quality of life parameters have been noted with DAA therapy. The results show improvement in HRQOL indices when interferon- free and particularly interferon and ribavirin- free treatments are compared to interferon and ribavirin treatment. Improvements in HRQOL indices are an encouraging aspect of the cure of chronic hepatitis C. It is unclear whether these measurable HRQOL improvements can be translated into a net benefit improvement in work productivity and a social dimension that is significant enough to convince payers of the added value of early and more widespread treatment.

 

K E Y W O R D S

antiviral treatment , health-related quality of life , hepatitis C , interferon , patient reported outcomes , sofosbuvir

About Speaker

Geoffrey DUSHEIKO

UK


Biography of Geoffrey DUSHEIKO

Geoffrey Dusheiko, MD, MB, BCh, is an emeritus professor of medicine at the Royal Free Hospital and University College London School of Medicine as well as a consultant hepatologist at King’s College Hospital, London, UK.

 

He earned his Bachelor of Medicine, Bachelor of Surgery degree from the University of Witwatersrand in Johannesburg, South Africa. After graduating, he completed his internship at Chris Hani Baragwanath Hospital in Johannesburg and his residency at Johannesburg Hospital. His fellowships were conducted at the Johannesburg Hospital Liver Unit, the National Institutes of Health (MD, USA), and the University of Minnesota (MN, USA).

 

Prof. Dusheiko’s research interests include the management and treatment of HCV, HBV, and small hepatocellular carcinoma. He has a special interest in research on viral hepatitis, particularly viral genotyping, applied molecular virology, the natural history of chronic viral hepatitis, and
antiviral therapies. A member of several organisations, including EASL, AASLD, and the International Association for the Study of the Liver (IASL),
Prof. Dusheiko is also a fellow of the Royal College of Physicians, the Royal College of Physicians of South Africa, and the Royal College of Physicians of Edinburgh. He served as educational councillor on the Governing Board of EASL for 4 years and was the recipient of the EASL Recognition Award in 2014.

 

In addition to being on the editorial board of the Journal of ViralEradication, he is co-editor of Alimentary Pharmacology and Therapeutics
and he has previously served on editorial boards for the Journal of Viral Hepatitis, Hepatology, Best Practice & Research: Clinical Gastroenterology, and Gut, among others. Prof. Dusheiko has authored or co-authored more than 400 articles published in international peer-reviewed journals or books.

View more